Discovery of tetrahydro-cyclopenta[b]indole as selective LXRs modulator.

A series of tetrahydro-cyclopenta[b]indoles modulating the activity of the liver-X-receptor (LXR) were derived from a high throughput screening hit. The potency and selectivity for LXRbeta versus LXRalpha was improved. One compound, administered to wild-type mice modestly increased plasma HDL-cholesterol with no change in plasma triglycerides (TG) and reduced effects on liver TG content compared to T0901317. This novel series of LXR agonists shows promise to improve therapeutic efficacy with reduced potential to increase TG.

[1]  Lisa Nogle,et al.  Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity. , 2008, Bioorganic & medicinal chemistry letters.

[2]  Chiaki Fukushima,et al.  Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators. , 2008, Journal of medicinal chemistry.

[3]  D. Mangelsdorf,et al.  Role of LXRs in control of lipogenesis. , 2000, Genes & development.

[4]  W. Quan,et al.  Enlargement of High Density Lipoprotein in Mice via Liver X Receptor Activation Requires Apolipoprotein E and Is Abolished by Cholesteryl Ester Transfer Protein Expression* , 2003, Journal of Biological Chemistry.

[5]  J. Medina,et al.  Discovery and optimization of a novel series of liver X receptor-α agonists , 2006 .

[6]  Angela Smallwood,et al.  Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. , 2008, Journal of medicinal chemistry.

[7]  P. Eacho,et al.  Liver X receptors as potential therapeutic targets for multiple diseases. , 2004, Drug news & perspectives.

[8]  Jörg Benz,et al.  Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β , 2006 .

[9]  A. Tall,et al.  LXR-Induced Redistribution of ABCG1 to Plasma Membrane in Macrophages Enhances Cholesterol Mass Efflux to HDL , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[10]  L L Iversen,et al.  Novel quinuclidine-based ligands for the muscarinic cholinergic receptor. , 1990, Journal of medicinal chemistry.

[11]  N. Mitro,et al.  LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. , 2004, Biochemical Society transactions.

[12]  Folkert Kuipers,et al.  Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-rich Very Low Density Lipoprotein Particles* , 2002, The Journal of Biological Chemistry.

[13]  Y. Morikawa,et al.  T‐0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor‐deficient mice , 2003, FEBS letters.

[14]  M. Brousseau.  Emerging role of high-density lipoprotein in the prevention of cardiovascular disease. , 2005, Drug discovery today.

[15]  T. Kirchgessner,et al.  Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator Published, JLR Papers in Press, June 1, 2004. DOI 10.1194/jlr.M300450-JLR200 , 2004, Journal of Lipid Research.

[16]  R. Krasuski.  HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study , 2005, Current opinion in lipidology.

[17]  J. Collins,et al.  Therapeutic opportunities for liver X receptor modulators. , 2004, Current opinion in drug discovery & development.

[18]  T. Stulnig,et al.  Liver X receptors in cardiovascular and metabolic disease , 2006, Cellular and Molecular Life Sciences.